Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
OPEN Journal for immunotherapy of cancer | 20 Sep 2017
HL Kaufman, RHI Andtbacka, FA Collichio, M Wolf, Z Zhao, M Shilkrut, I Puzanov and M Ross
Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response] beginning within 12 months of treatment and lasting ≥6 months) have been employed. There has not, however, been validation that DRR correlates with other more traditional endpoints of clinical benefit such as overall survival.
* Data courtesy of Altmetric.com